Beijing Tongren Hospital

Researchers are testing efgartigimod, an intravenous drug that reduces certain antibodies, in adults with anti-NMDAR encephalitis, a rare autoimmune condition that causes psychiatric symptoms, seizures, and movement problems. The trial enrolls 20 participants who receive four wee…

This study tests a new absorbable stent that releases medication to keep the tear duct open after surgery for recurrent chronic dacryocystitis (blocked tear ducts). Forty adults who have had a previous failed surgery will be randomly assigned to receive either the new stent or st…

This early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with head and neck cancer that has come back or spread. All participants have already tried standard treatments. The main goals are to see if the combination is safe and whether it shrinks…

This phase 2 trial tests a combination of three drugs—pomalidomide, tislelizumab, and selinexor—in 43 people with relapsed or refractory primary central nervous system lymphoma. The goal is to see if this cocktail can shrink tumors and improve survival. All participants receive t…

This trial tests a new combination of drugs (MEPL-G) for people with a rare and aggressive lymphoma (NK/T-cell) that has triggered a life-threatening immune overreaction called HLH. The goal is to control both the cancer and the dangerous inflammation quickly. About 25 adults wil…

This phase 2 trial tests whether adding the drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who have high-risk features. About 50 participants will receive the combination…

This study tests a drug called orelabrutinib, alone or with another drug (CD20 antibody), in 88 people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. Participants take the drug daily for 6 cycles, and those with mo…

This study tests two types of special glasses (D.S.D.O. lenses) designed to slow the progression of nearsightedness (myopia) in children aged 6 to 14. About 120 children will wear the glasses daily for one year and have regular eye checkups. The goal is to see if these lenses can…

This study tests a new antibody drug for people whose seasonal allergies (hay fever) are not controlled by standard treatments. The drug targets a protein involved in allergic inflammation. About 120 adults will receive either the antibody or a placebo, and researchers will measu…

This study looks at how high blood pressure, diabetes, and high cholesterol affect the tiny blood vessels in the back of the eye. Researchers will use a special, non-invasive camera to take detailed images of the retina and track changes over five years. The goal is to see if eye…